Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunotherapy after bone marrow transplantation.

H G Klingemann1, G L Phillips

  • 1Division of Hematology, BC Cancer Agency, Vancouver General Hospital, Canada.

Bone Marrow Transplantation
|August 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intensive post-remission therapy does not decrease relapse after allotransplants for acute myeloid leukaemia in 1st remission and should not be given.

Leukemia·2025
Same author

A modest proposal to the transplant publik to prevent harm to people with acute myeloid leukaemia in 1st complete remission cured by chemotherapy.

Leukemia·2024
Same author

A randomized study of melphalan 200 mg/m(2) vs 280 mg/m(2) as a preparative regimen for patients with multiple myeloma undergoing auto-SCT.

Bone marrow transplantation·2015
Same author

Platelet transfusion and survival in adults with acute leukemia.

Leukemia·2007
Same author

What would Karl Landsteiner do? The ABO blood group and stem cell transplantation.

Bone marrow transplantation·2005
Same author

Phase I study for poor-prognosis lymphoma: augmentation of the "BEAM" regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation--a preliminary report.

Seminars in oncology·2005
Same journal

CHIME: a novel HLA eplet model associates with non-relapse mortality in haploidentical hematopoietic cell transplant with post-transplant cyclophosphamide.

Bone marrow transplantation·2026
Same journal

Transplant outcomes for patients with severe acquired aplastic anemia over the age of 40 using busulfan, fludarabine, reduced-dose cyclophosphamide, and anti-thymocyte globulin conditioning regimen.

Bone marrow transplantation·2026
Same journal

A holistic prognostic model for leukemia-free survival after allogeneic transplantation in acute leukemia.

Bone marrow transplantation·2026
Same journal

Early software-assisted response predicts survival in a prospective cohort of 258 newly diagnosed cGvHD patients.

Bone marrow transplantation·2026
Same journal

Evaluation of a novel eHealth-facilitated, post HCT-integrated care model on implementation and rehospitalization: results from the Swiss SMILe hybrid-RCT.

Bone marrow transplantation·2026
Same journal

Impact of doublet post-transplant maintenance on outcomes in multiple myeloma: A propensity score matching analysis.

Bone marrow transplantation·2026
See all related articles

Residual disease after bone marrow transplantation (BMT) can be controlled by immune mechanisms, including graft-versus-leukemia (GVL). Cytokines are being explored to enhance GVL and eliminate residual leukemia post-BMT.

Area of Science:

  • Immunology
  • Oncology
  • Hematology

Background:

  • Residual disease post-bone marrow transplantation (BMT) can lead to relapse or be controlled by immune mechanisms.
  • The graft-versus-leukemia (GVL) effect, mediated by cellular and humoral factors, is crucial for controlling residual leukemia after allogeneic BMT.
  • GVL is often associated with graft-versus-host disease (GVHD).

Purpose of the Study:

  • To review preclinical and clinical studies on immune modulation to eliminate residual malignant disease after BMT.
  • To explore the role of cytokines in supporting cellular immune function post-BMT.
  • To inform the design of therapeutic protocols aimed at improving GVL efficacy.

Main Methods:

  • Review of preclinical research on immune responses after BMT.

Related Experiment Videos

  • Analysis of clinical trial data involving cytokine therapy post-BMT.
  • Synthesis of findings related to GVL and GVHD.

    • Main Results:

    • Emerging studies investigate cytokine administration (e.g., interleukin-2, interferons) to bolster anti-leukemia immunity.
    • Cytokine therapy aims to enhance cellular immune function, particularly when GVL is insufficient.
    • Evidence suggests potential for immune system modulation to improve residual disease control.

    Conclusions:

    • Immune system modulation, especially through cytokine therapy, holds promise for enhancing graft-versus-leukemia effects.
    • Further research is needed to optimize protocols for leveraging immune mechanisms against residual leukemia post-BMT.
    • Targeting immune function post-BMT is a key strategy for preventing relapse and improving patient outcomes.